Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 83 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) (i) Disaggregation of revenue from contracts with customers (Continued) For the year ended 31 December 2024 Intermediate Bulk Finished Segments products medicine products Total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Types of products – 6-APA 1,857,922 – – 1,857,922 – 1,857,922 – Antibiotics products – 6,362,746 3,179,585 9,542,331 – 9,542,331 – Insulin products – – 1,182,676 1,182,676 – 1,182,676 – Others 800,769 9,937 365,302 1,176,008 – 1,176,008 Revenue from contracts with customers 2,658,691 6,372,683 4,727,563 13,758,937 – 13,758,937 Inter-segment sales 3,198,429 979,071 – 4,177,500 (4,177,500) – Segment revenue 5,857,120 7,351,754 4,727,563 17,936,437 (4,177,500) 13,758,937 All of the Group’s revenue is recognised at a point in time during the years ended 31 December 2025 and 2024.